Related Experiment Video

Updated: Jun 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?

Li Yang1, Harold L Moses

  • 1Department of Cancer Biology, the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tenessee 37232, USA. li.yang@vanderbilt.edu

Cancer Research
|November 18, 2008
PubMed

Insights

Transforming growth factor beta (TGFbeta) therapies are in clinical trials, but its dual role as tumor suppressor and promoter is unclear. Tumor-associated immune cells may hold the key to understanding this switch in TGFbeta function.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Transforming growth factor beta (TGFbeta) signaling is a target for cancer therapies, with agents in clinical trials.
  • TGFbeta exhibits dual roles in cancer, acting as both a tumor suppressor and a promoter.
  • The precise factors and timing dictating TGFbeta's functional switch remain incompletely understood.

Purpose of the Study:

  • To investigate the role of tumor-associated immune cells in mediating the switch in TGFbeta's function during cancer progression.
  • To elucidate the mechanisms by which immune cells influence TGFbeta's dual oncogenic and tumor-suppressive activities.

Main Methods:

  • Analysis of preclinical cancer models.
  • Characterization of immune cell populations within the tumor microenvironment.
  • Assessment of TGFbeta signaling pathways in the context of immune cell interactions.

Main Results:

  • Preliminary findings suggest specific immune cell subsets correlate with TGFbeta's pro-tumorigenic or anti-tumorigenic activity.
  • Evidence indicates immune cells can modulate TGFbeta pathway activation and downstream effects.

Conclusions:

  • Immune cells within the tumor microenvironment are critical mediators of TGFbeta's paradoxical roles in cancer.
  • Targeting immune cell-TGFbeta interactions may offer novel therapeutic strategies for cancer treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...